Literature DB >> 17909360

Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.

Raja M Flores1, Maureen Zakowski, Ennapadam Venkatraman, Lee Krug, Kenneth Rosenzweig, Joseph Dycoco, Catherine Lee, Cindy Yeoh, Manjit Bains, Valerie Rusch.   

Abstract

INTRODUCTION: Most studies describing the natural history and prognostic factors for malignant pleural mesothelioma antedate accurate pathologic diagnosis, staging by computed tomography, and a universal staging system. We conducted a large single-institution analysis to identify prognostic factors and assess the association of resection with outcome in a contemporary patient population.
METHODS: Patients with biopsy-proven malignant pleural mesothelioma at our institution were identified and clinical data were obtained from an institutional database. Survival and prognostic factors were analyzed by the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis. A p value <0.05 was considered statistically significant.
RESULTS: From 1990 to 2005, 945 patients were identified: 755 men, 190 women; median age, 66 years (range, 26-93). Extrapleural pneumonectomy was performed in 208 (22%), pleurectomy/decortication in 176 (19%). Operative mortality was 4% (16/384). Multimodality therapy including surgery was associated with a median survival of 20.1 months. Significant predictors of overall survival included histology, gender, smoking, asbestos exposure, laterality, surgical resection by extrapleural pneumonectomy or pleurectomy/decortication, American Joint Committee on Cancer stage, and symptoms. A Cox model demonstrated a hazard ratio of 1.4 without surgical resection when controlling for histology, stage, gender, asbestos exposure, smoking history, symptoms, and laterality (p = 0.003).
CONCLUSIONS: In addition to tumor histology and pathologic stage, predictors of survival include gender, asbestos exposure, smoking, symptoms, laterality, and clinical stage. Surgical resection in a multimodality setting was associated with improved survival.

Entities:  

Mesh:

Year:  2007        PMID: 17909360     DOI: 10.1097/JTO.0b013e31815608d9

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  65 in total

1.  Mesothelioma: a review.

Authors:  Frank E Mott
Journal:  Ochsner J       Date:  2012

Review 2.  A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.

Authors:  Elaine Teh; Francesca Fiorentino; Carol Tan; Tom Treasure
Journal:  J R Soc Med       Date:  2011-02       Impact factor: 5.344

3.  Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?

Authors:  Mehmet Ali Bedirhan; Levent Cansever; Adalet Demir; Süleyman Ceyhan; Hasan Akın; Halide Nur Urer; Aysun Olçmen; Celalettin Kocatürk; Ibrahim Dinçer
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

4.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

5.  Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.

Authors:  Valerie W Rusch
Journal:  Ann Cardiothorac Surg       Date:  2012-11

6.  Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.

Authors:  Hari B Keshava; Andrew Tang; Hafiz Umair Siddiqui; Siva Raja; Daniel P Raymond; Alejandro Bribriesco; James Stevenson; Sudish C Murthy; Usman Ahmad
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

7.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jun-Ichi Nitadori; Joachim G Aerts; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Lee M Krug; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

8.  Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Authors:  Raffit Hassan; Anish Thomas; John J Nemunaitis; Manish R Patel; Jaafar Bennouna; Franklin L Chen; Jean-Pierre Delord; Afshin Dowlati; Samith T Kochuparambil; Matthew H Taylor; John D Powderly; Ulka N Vaishampayan; Claire Verschraegen; Hans Juergen Grote; Anja von Heydebreck; Kevin Chin; James L Gulley
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

9.  Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Authors:  Maaike Van Gerwen; Naomi Alpert; Andrea Wolf; Nisha Ohri; Erik Lewis; Kenneth E Rosenzweig; Raja Flores; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

10.  A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Authors:  Stephanie R Rice; Yun R Li; Theresa M Busch; Michele M Kim; Sally McNulty; Andrea Dimofte; Timothy C Zhu; Keith A Cengel; Charles B Simone
Journal:  Photochem Photobiol       Date:  2018-12-28       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.